Back to Results
First PageMeta Content
Diabetes / Metabolism / Insulin resistance / Myostatin / Familial hypercholesterolemia / Low-density lipoprotein / FGF21 / Metabolic syndrome / Apolipoprotein B / Biology / Medicine / Health


ORIGINAL ARTICLE Genetic Disruption of Myostatin Reduces the Development of Proatherogenic Dyslipidemia and Atherogenic Lesions In Ldlr Null Mice Powen Tu,1 Shalender Bhasin,1,2 Paul W. Hruz,3 Karen L. Herbst,4 Lawrence
Add to Reading List

Open Document

File Size: 544,74 KB

Share Result on Facebook

City

Waukesha / Holliston / Houston / Hercules / Tarrytown / Bradford / Pittsburgh / Columbus / Indianapolis / St. Louis / Santa Cruz / Salem / Bedford / Valencia / Boston / Shelton / Madison / La Jolla / Billerica / Atlanta / Danvers / Foster City / Torrance / /

Company

Eli Lilly / Jackson Laboratory / Agilent Technologies / Sigma Aldrich / Proc Natl Acad Sci U S A / Thermo Electron / Cardiovascular Specialty Laboratories / Qiagen / Newman AB / DIABETES / Bio-Rad / PerkinElmer / Abbott Laboratories / Charron MJ HF L. / Bayer / P. TU AND ASSOCIATES / Matsuda / Becton Dickinson / Parsons SA / /

Country

Sudan / United States / /

/

Event

FDA Phase / Product Issues / /

Facility

Bar Harbor / University of California Los Angeles / Bethel MA / University School / Boston Medical Center / University of California San Diego / Fort Scott / /

IndustryTerm

online appendix / Visceral and subcutaneous fat imaging / therapies for heart disease / food / energy / Food consumption / energy intake / Diabetes Care / mice / Treatment of diabetes / Study protocols / insulin product / reduced food intake / treatment of obesity / /

MedicalCondition

chronic illnesses / H eart disease / diet-induced atherogenesis / ischemic heart disease / Proatherogenic Dyslipidemia / fatal myocardial infarction / mixed insulin resistance / hepatic insulin resistance / hypercholesterolemia and atheromatous lesions / significantly higher peripheral glucose DIABETES / atherogenesis / non-alcoholic fatty liver disease / dyslipidemia / diabetes / metabolic syndrome / cardiometabolic diseases / prevalent disorders / cardiometabolic disorders / MYOSTATIN DEFICIENCY AND ATHEROSCLEROSIS / muscular dystrophy / MYOSTATIN DEFICIENCY AND ATHEROSCLEROSIS H / twofold DIABETES / TB / acute and reversible peripheral insulin resistance / heart disease / obesity / reduced atherogenesis / familial hypercholesterolemia / MS / active antiretroviral therapy-associated metabolic syndrome / online DIABETES / insulin resistance / significant DIABETES / disease / atherosclerosis / obesity-induced insulin resistance / cardiovascular disease / hyperlipidemia / diabetes mellitus / NIDDM / fatty liver / accelerated atherogenesis / Inflammation / diet-induced obesity / aortic atherogenesis / /

MedicalTreatment

highly active antiretroviral therapy / surgery / catheter / /

Organization

University of California Los Angeles / Los Angeles / Boston University School of Medicine / Boston University’s Institutional Animal Care and Use Committee / Department of Medicine / Washington University School of Medicine / African Union / US Federal Reserve / University of California San Diego / San Diego / Harvard Medical School / Internal Revenue Service / Harvard / American Diabetes Association / United Nations / Boston Medical Center / /

Person

Ann Neurol / Van Citters / Sakura Finetech / Frederick / Defective / Arch Intern / /

Position

mediator / King / Representative / Bernard PM / Corresponding author / Smiths Medical PM / Warden / /

Product

glucagon / Dextrose / isoflurane / MYO-029 / regulation / /

ProvinceOrState

Quebec / Washington / Missouri / California / Massachusetts / /

PublishedMedium

PLoS ONE / /

RadioStation

Shea AM / Lawler AM / /

Technology

X-ray / stem cells / Cell Signaling Technology / gene expression / genotype / FLASH / tomography / antibodies / Biotechnology / Study protocols / drug development / /

URL

http /

SocialTag